Stocktoria
Syndax Pharmaceuticals Inc SNDX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-03-03
Syndax Pharmaceuticals Inc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -158.4% | -1434.4% | — | — | 18.8% |
| Net margin | -165.6% | -1346.1% | — | — | 17.8% |
| FCF margin | -187.5% | -1160.9% | — | — | 20.8% |
| Return on assets | -53.9% | -44.0% | -34.2% | -30.0% | 5.5% |
| Return on equity | -441.6% | -110.6% | -37.8% | -31.9% | 6.1% |
| Current ratio | 4.40 | 5.82 | 10.00 | 16.85 | 21.68 |
| Revenue growth | 627.8% | — | — | -100.0% | 9109.6% |
Source: SEC EDGAR filings · CIK 0001395937 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.